Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,981 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride (NaCl) Clear all
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

NCT06565650
View directory record Official record
Conditions
Dry Eye
Interventions
Miebo, Saline
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Glendale, California • Murrieta, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 16, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Ketamine for Methamphetamine Use Disorder

NCT06496750
View directory record Official record
Conditions
Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions
Ketamine Hydrochloride, Midazolam Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept (POC) in Patients With Ischaemic Stroke

NCT01808261
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320 100/mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Perioperative Ketamine Infusion on Surgical Recovery

NCT04625283
View directory record Official record
Conditions
Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 16, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783
View directory record Official record
Conditions
Influenza A
Interventions
VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
51
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 9:22 AM EDT
Not listed Phase 4 Interventional

Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients

NCT03049930
View directory record Official record
Conditions
Burns
Interventions
Ketamine, Sodium chloride
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 16, 2026, 9:22 AM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Study of KCC Peptide Application in the Colon

NCT02156557
View directory record Official record
Conditions
Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions
Colon KCC Heptapeptide
Biological
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 16, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, normal saline
Drug · Other
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
12 Years and older
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 16, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement

NCT02540226
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Intravenous tranexamic acid, Topical tranexamic acid, Intravenous saline, Topical saline
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

NCT05330078
View directory record Official record
Conditions
Keloid
Interventions
Botulinum toxin type A, Vehicle
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 16, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger

NCT02722200
View directory record Official record
Conditions
Obesity
Interventions
hydrocortisone, saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 16, 2026, 9:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

NCT05604521
View directory record Official record
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

NCT02597647
View directory record Official record
Conditions
Influenza
Interventions
LAIV, Saline
Biological · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 16, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

NCT07192458
View directory record Official record
Conditions
Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions
Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

NCT01290367
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Single Dose MPCs Injection, Single injection of saline solution, Single injection of hyaluronic acid
Biological · Procedure
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 16, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin for the Management of Chronic Orchialgia

NCT02058836
View directory record Official record
Conditions
Chronic Testicular Pain
Interventions
Botox Injection, Normal saline injection
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 16, 2026, 9:22 AM EDT
Withdrawn Phase 1 Interventional

Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

NCT02823106
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil and Citicoline, Placebo
Drug · Other
Lead sponsor
Justin Fraser
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 16, 2026, 9:22 AM EDT